Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.

MLA

Haigentz, Missak, et al. “Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.” The Oncologist, vol. 27, no. 8, Aug. 2022, p. 623. EBSCOhost, https://doi.org/10.1093/oncolo/oyac004.

APA

Haigentz, M., Moore, P., Bimali, M., Cooley, T., Sparano, J., Rudek, M., Ratner, L., Henry, D., Ramos, J., Deeken, J., Rubinstein, P., & Chiao, E. (2022). Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. The Oncologist, 27(8), 623. https://doi.org/10.1093/oncolo/oyac004

Chicago

Haigentz, Missak, Page Moore, Milan Bimali, Timothy Cooley, Joseph Sparano, Michelle Rudek, Lee Ratner, et al. 2022. “Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.” The Oncologist 27 (8): 623. doi:10.1093/oncolo/oyac004.